CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Revenue:
Total revenue	$ 157,370	$ 114,305	$ 300,907	$ 211,155
Cost of revenue:
Total cost of revenue	60,781	45,044	116,090	81,932
Gross profit	96,589	69,261	184,817	129,223
Operating expenses:
Research, development and clinical trials	15,934	13,858	33,094	25,238
Selling, general and administrative	44,088	42,895	87,713	79,056
Total operating expenses	60,022	56,753	120,807	104,294
Income from operations	36,567	12,508	64,010	24,929
Other income (expense):
Interest expense	(3,476)	(3,623)	(6,937)	(7,221)
Interest income and other income (expense)	3,091	3,268	5,785	6,838
Total other expense, net	(385)	(355)	(1,152)	(383)
Income before income taxes	36,182	12,153	62,858	24,546
(Provision) benefit for income taxes	(1,275)	41	(2,269)	(155)
Net income	$ 34,907	$ 12,194	$ 60,589	$ 24,391
Net income per share, basic	$ 1.03	$ 0.37	$ 1.79	$ 0.74
Net income per share, diluted	$ 0.92	$ 0.35	$ 1.62	$ 0.7
Weighted average common shares outstanding, basic	33,912,669	33,119,514	33,817,664	32,939,852
Weighted average common shares outstanding, diluted	40,558,953	35,288,308	40,238,501	34,983,603
Net product revenue [Member]
Revenue:
Total revenue	$ 96,100	$ 71,732	$ 184,334	$ 133,057
Cost of revenue:
Total cost of revenue	19,421	14,470	35,733	28,554
Service Revenue [Member]
Revenue:
Total revenue	61,270	42,573	116,573	78,098
Cost of revenue:
Total cost of revenue	$ 41,360	$ 30,574	$ 80,357	$ 53,378